Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in Adaptimmune's phase 2 SPEARHEAD-1 trial
Adaptimmune Therapeutics plc reports initial data from its Phase 2 SPEARHEAD-1 trial showing a high response rate of 41.4% for patients with synovial sarcoma, including two complete responses and encouraging initial safety and durability. The trial's results support the company's BLA submission next year.